Development of a Mobile Health Intervention to Support Functioning of Veterans With Substance Use Disorders
8 de junho de 2026 atualizado por: VA Office of Research and Development
This project will involve the development, refinement, and preliminary testing of a mobile health intervention (Motivational Enhancement Therapy Skills for Veterans; "METS4Vets"), which will be delivered through a smartphone app.
The intervention will aim to support Veterans who are navigating the critical transition from structured residential substance use treatment to outpatient settings.
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Intervenção / Tratamento
Descrição detalhada
This project will involve the development, refinement, and pilot testing of a beta version of a mobile health intervention (Motivational Enhancement Therapy Skills for Veterans; "METS4Vets"), which will be delivered through a smartphone app.
Phase I: Preliminary METS4Vets content will be developed by the research team. Content will be developed by integrating research literature on digital interventions, evidence-based skills content derived from Motivational Enhancement Therapy, the "spirit" of Motivational Interviewing (e.g., using non-judgmental phrasing), and VA's existing My Recovery Plan framework. After preliminary content is developed, the research team will then solicit feedback on the proposed content through qualitative interviews with Veterans engaged in residential substance use treatment programming at VA (n=10) and VA clinicians who treat Veterans with substance use disorders (n=10).
Phase II: Using the content developed in Phase I, the investigators will conduct iterative, single session system acceptability and usability testing with Veterans engaged in residential substance use treatment programming at VA (n=12-15).
Tipo de estudo
Intervencional
Inscrição (Estimado)
30
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Shannon Schrader, PhD
- Número de telefone: (203) 892-3624
- E-mail: shannon.schrader@va.gov
Locais de estudo
-
-
Connecticut
-
West Haven, Connecticut, Estados Unidos, 06516-2770
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT
-
Contato:
- Shannon Schrader, PhD
- Número de telefone: 203-892-3624
- E-mail: shannon.schrader@va.gov
-
Investigador principal:
- Shannon Schrader, PhD
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Sim
Descrição
Inclusion Criteria:
- current SUD diagnosis according to chart review
- current enrollment in VACHS residential SUD treatment program
- competent to provide written informed consent
- a working smartphone with wireless capabilities or willingness to use a study-provided smartphone
Exclusion Criteria:
- current psychosis
- current active suicidal/homicidal ideation
- physical disability (e.g., uncorrected vision) that would preclude use of smartphones and/or smartphone applications
- cognitive impairment that would interfere with study participation or ability to provide informed consent, as determined by clinical interview
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention
Intervention condition
|
Motivational Enhancement Therapy Skills for Veterans mobile app based intervention
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Intervention Usability (Systems Usability Scale)
Prazo: Through 3-month follow-up assessment
|
The Systems Usability Scale (SUS) will be used to assess the perceived usability of the intervention.
The SUS is a 10-item Likert-type self-report measure that generates a subjective score to assess whether the system is sufficiently usable in its current form.
Responses range from 0 to 4 with a total score ranging from 0 - 100.
A score above 68 is considered above average while scores above 80 are considered highly favorable and indicative of recommending the product to friends.
|
Through 3-month follow-up assessment
|
|
Intervention Acceptability (mHealth Satisfaction Questionnaire)
Prazo: Through 3-month follow-up assessment
|
The mHealth Satisfaction Questionnaire will be used to assess acceptability of the intervention.
The mHealth Satisfaction Questionnaire is a 14-item self-report measure that assesses the level of user satisfaction and acceptability with the app, its interface, and its content.
Responses range from 1 (strongly disagree) to 5 (strongly agree) Higher scores reflect greater satisfaction.
Total scores can range from 14 to 70.
|
Through 3-month follow-up assessment
|
|
Study Feasibility (rates of attrition)
Prazo: Through 6-month follow-up assessment
|
The rate of participant attrition across the total study period.
Rates could potentially range from 0%-100% with higher attrition rates representing worse feasibility.
|
Through 6-month follow-up assessment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Psychosocial functioning (Brief Inventory of Psychosocial Functioning)
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6 month follow-up in self-reported psychosocial functioning will be assessed via the Brief Inventory of Psychosocial Functioning (B-IPF), which is a 7-item scale with each item ranging from 0 ("not at all") to 6 ("very much").
Total scores can range from 0 to 42 with higher scores indicating worse psychosocial functioning.
The B-IPF assesses different domains of psychosocial functioning including social functioning, occupational functioning, and participation in daily tasks.
|
Through 6-month follow-up
|
|
Substance use
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6-month follow-up in self-reported substance use including frequency and quantity of alcohol use and frequency of drug use.
This will be collected by asking Veterans (yes/no) whether they drank alcohol or used any illicit substances in the past 24 hours.
For Veterans who endorse alcohol use, they will be asked how many standard drinks they consumed.
For Veterans who respond affirmatively to illicit substance use, they will be asked to indicate which substance(s) they used (e.g., cannabis, cocaine, heroin).
|
Through 6-month follow-up
|
|
Sleep
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6-month follow-up in self-reported sleep quality.
This will be assessed by asking Veterans to 1) rate their perceived sleep quality on a 0 ("extremely poor") to 8 ("extremely rested") Likert-type scale; total scores can range from 0 to 8 with higher scores representing better subjective sleep quality; and 2) indicate how many hours of sleep they got on an average night in the assessment timeframe period.
|
Through 6-month follow-up
|
|
Quality of Life (VR-12)
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6-month follow-up in self-reported quality of life assessed via the Veterans RAND 12-Item Health Survey (VR-12), which assesses health-related quality of life including domains of physical functioning, bodily pain, and social functioning.
The VR-12 consists of 12 items on a 5-point Likert scale (0 to 5) with higher scores representing better quality of life.
Total scores can range from 0 to 60.
|
Through 6-month follow-up
|
|
Quality of Life (VAS)
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6-month follow-up in self-reported quality of life assessed via a single-item Visual Analog Scale (VAS).
The VAS asks respondents to rate their global quality of life on a scale from 0 ("worst possible quality of life") to 100 ("best possible quality of life").
Total scores can range from 0 to 100 with higher scores representing better quality of life.
|
Through 6-month follow-up
|
|
Substance Use (ASI)
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6-month follow-up in substance use will be assessed using the Addiction Severity Index (ASI).
The ASI queries about seven potential problem areas impacted by substance use.
Scores on the seven domains can range from 0-1: No imminent problem, treatment not indicated.
2-3: Slight problem; treatment may not be necessary.
4-5: Moderate problem, a treatment plan should be considered.
6-7: Considerable difficulty, begin a treatment plan.
Total scores can range from 0 to 49 with higher scores representing worse substance use severity.
|
Through 6-month follow-up
|
|
Treatment engagement
Prazo: Through 6-month follow-up
|
Changes from pre-intervention to 6-month follow-up in self-reported treatment engagement.
This will be collected by asking Veterans (yes/no) whether they attended any treatment appointments in the follow-up assessment timeframe including self-help groups (AA, NA), VA appointments, or community-based appointments.
|
Through 6-month follow-up
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Shannon Schrader, PhD, VA Connecticut Healthcare System West Haven Campus, West Haven, CT
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de outubro de 2026
Conclusão Primária (Estimado)
30 de setembro de 2031
Conclusão do estudo (Estimado)
30 de setembro de 2031
Datas de inscrição no estudo
Enviado pela primeira vez
2 de junho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
8 de junho de 2026
Primeira postagem (Real)
12 de junho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
12 de junho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
8 de junho de 2026
Última verificação
1 de junho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RRD9-008-25W
- RD001916-01A1 (Identificador de registro: Department of Veteran Affairs)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .